Association Between US Norepinephrine Shortage and Mortality Among Patients With Septic Shock.
Drug shortages in the United States are common, but their effect on patient care and outcomes has rarely been reported.



To assess changes to patient care and outcomes associated with a 2011 national shortage of norepinephrine, the first-line vasopressor for septic shock.



Retrospective cohort study of 26 US hospitals in the Premier Healthcare Database with a baseline rate of norepinephrine use of at least 60% for patients with septic shock. The cohort included adults with septic shock admitted to study hospitals between July 1, 2008, and June 30, 2013 (n = 27 835).



Hospital-level norepinephrine shortage was defined as any quarterly (3-month) interval in 2011 during which the hospital rate of norepinephrine use decreased by more than 20% from baseline.



Use of alternative vasopressors was assessed and a multilevel mixed-effects logistic regression model was used to evaluate the association between admission to a hospital during a norepinephrine shortage quarter and in-hospital mortality.



Among 27 835 patients (median age, 69 years [interquartile range, 57-79 years]; 47.0% women) with septic shock in 26 hospitals that demonstrated at least 1 quarter of norepinephrine shortage in 2011, norepinephrine use among cohort patients declined from 77.0% (95% CI, 76.2%-77.8%) of patients before the shortage to a low of 55.7% (95% CI, 52.0%-58.4%) in the second quarter of 2011; phenylephrine was the most frequently used alternative vasopressor during this time (baseline, 36.2% [95% CI, 35.3%-37.1%]; maximum, 54.4% [95% CI, 51.8%-57.2%]). Compared with hospital admission with septic shock during quarters of normal use, hospital admission during quarters of shortage was associated with an increased rate of in-hospital mortality (9283 of 25 874 patients [35.9%] vs 777 of 1961 patients [39.6%], respectively; absolute risk increase = 3.7% [95% CI, 1.5%-6.0%]; adjusted odds ratio = 1.15 [95% CI, 1.01-1.30]; P = .03).



Among patients with septic shock in US hospitals affected by the 2011 norepinephrine shortage, the most commonly administered alternative vasopressor was phenylephrine. Patients admitted to these hospitals during times of shortage had higher in-hospital mortality.
Department of Anesthesiology, Columbia University, New York, New York.
Emily
E
Vail
Department of Medicine, Albert Einstein College of Medicine, Montefiore Medical Center, Bronx, New York3Department of Neurology, Albert Einstein College of Medicine, Montefiore Medical Center, Bronx, New York.
Hayley B
HB
Gershengorn
Department of Anesthesiology, Columbia University, New York, New York4Department of Epidemiology, Columbia University Mailman School of Public Health, New York, New York.
May
M
Hua
Pulmonary Center, Boston University School of Medicine, Boston, Massachusetts6Evans Center for Implementation and Improvement Sciences, Boston University School of Medicine, Boston, Massachusetts.
Allan J
AJ
Walkey
Department of Medicine, University of Toronto, Toronto, Ontario, Canada8Interdepartmental Division of Critical Care Medicine, University of Toronto, Toronto, Ontario, Canada9Department of Critical Care Medicine, Sunnybrook Health Sciences Centre, Toronto, Ontario, Canada.
Gordon
G
Rubenfeld
Department of Anesthesiology, Columbia University, New York, New York8Interdepartmental Division of Critical Care Medicine, University of Toronto, Toronto, Ontario, Canada9Department of Critical Care Medicine, Sunnybrook Health Sciences Centre, Toronto, Ontario, Canada10Department of Anesthesia, University of Toronto, Toronto, Ontario, Canada.
Hannah
H
Wunsch
D000368:Aged; D016208:Databases, Factual / Q000706:statistics & numerical data; D005260:Female; D017052:Hospital Mortality; D006801:Humans; D008297:Male; D008875:Middle Aged; D009638:Norepinephrine / Q000600:supply & distribution* / Q000627:therapeutic use; D017063:Outcome Assessment, Health Care; D010656:Phenylephrine / Q000627:therapeutic use; D012189:Retrospective Studies; D012772:Shock, Septic / Q000188:drug therapy / Q000401:mortality*; D014481:United States; D014662:Vasoconstrictor Agents / Q000600:supply & distribution* / Q000627:therapeutic use
D014662:Vasoconstrictor Agents; D010656:Phenylephrine; D009638:Norepinephrine